{"id":"decitabine-and-cytarabine","safety":{"commonSideEffects":["Myelosuppression","Neutropenia","Thrombocytopenia","Anemia","Febrile neutropenia","Nausea","Fatigue"]},"_chembl":null,"modality":"Small molecule","_dailymed":null,"mechanism":{"target":"DNA methyltransferase (DNMT) and DNA polymerase","explanation":"Decitabine inhibits DNA methyltransferases, leading to hypomethylation and reactivation of tumor suppressor genes. Cytarabine, a cytidine analog, incorporates into DNA and inhibits DNA polymerase, blocking DNA synthesis and repair. Together, they provide complementary mechanisms to eliminate malignant cells.","oneSentence":"Combines DNA methyltransferase inhibition with nucleoside analog-mediated DNA synthesis disruption to target cancer cells."},"_scrapedAt":"2026-03-28T03:31:46.677Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779122864,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"azacitidine","brand":"Vidaza","company":"Celgene","rationale":"Hypomethylating agent for AML and MDS"},{"name":"venetoclax plus azacitidine","brand":"Venclexta","company":"AbbVie","rationale":"Combination therapy approved for AML"},{"name":"decitabine","brand":"Dacogen","company":"Janssen","rationale":"Single-agent hypomethylating therapy for MDS and AML"}],"description":"Decitabine and cytarabine is a combination therapy being investigated for hematologic malignancies. Decitabine is a hypomethylating agent that inhibits DNA methyltransferase, while cytarabine is a nucleoside analog that interferes with DNA synthesis. This combination is being studied in Phase 2 trials for blood cancers.","indications":{"approved":[{"status":"investigational","condition":"Acute myeloid leukemia","patientPopulation":"Adult"},{"status":"investigational","condition":"Myelodysplastic syndromes","patientPopulation":"Adult"}]},"trialDetails":[{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT01627041","phase":"PHASE2","title":"Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-09-16","conditions":"Acute Myeloid Leukemia, Adult Acute Basophilic Leukemia, Adult Acute Monoblastic Leukemia","enrollment":178},{"nctId":"NCT07101588","phase":"PHASE4","title":"Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-01-01","conditions":"Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)","enrollment":200},{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT06713837","phase":"PHASE3","title":"IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.","status":"RECRUITING","sponsor":"Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS","startDate":"2025-02-27","conditions":"Acute Myeloid Leukemia, Relapse/Recurrence","enrollment":339},{"nctId":"NCT03226418","phase":"PHASE2","title":"Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2017-07-07","conditions":"Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia","enrollment":75},{"nctId":"NCT07060001","phase":"PHASE2","title":"Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker","status":"NOT_YET_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-04","conditions":"Acute Myeloid Leukemia (AML), Acute Myeloid Leukaemia (AML)","enrollment":112},{"nctId":"NCT07451912","phase":"PHASE1, PHASE2","title":"Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-09-15","conditions":"Acute Myeloid Leukemia (AML), CEBPA Mutation, Unfit, New-diagnosis AML","enrollment":29},{"nctId":"NCT04263181","phase":"","title":"AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2020-01-29","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":80},{"nctId":"NCT01515527","phase":"PHASE2","title":"Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-02-07","conditions":"Leukemia","enrollment":160},{"nctId":"NCT03164057","phase":"PHASE2","title":"A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2017-06-15","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":206},{"nctId":"NCT03926624","phase":"PHASE3","title":"Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage","status":"TERMINATED","sponsor":"Delta-Fly Pharma, Inc.","startDate":"2019-11-22","conditions":"Leukemia, Myeloid, Acute","enrollment":167},{"nctId":"NCT03013998","phase":"PHASE1, PHASE2","title":"Study of Biomarker-Based Treatment of Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Beat AML, LLC","startDate":"2016-11","conditions":"Previously Untreated Relapsed Refractory Acute Myeloid Leukemia","enrollment":3000},{"nctId":"NCT04817241","phase":"PHASE1, PHASE2","title":"Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-02-10","conditions":"Acute Myeloid Leukemia","enrollment":5},{"nctId":"NCT06928662","phase":"PHASE1, PHASE2","title":"Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-09-23","conditions":"Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia","enrollment":36},{"nctId":"NCT03263936","phase":"PHASE1","title":"Epigenetic Reprogramming in Relapse/Refractory AML","status":"COMPLETED","sponsor":"Therapeutic Advances in Childhood Leukemia Consortium","startDate":"2017-07-11","conditions":"Acute Myelogenous Leukemia","enrollment":37},{"nctId":"NCT03068819","phase":"PHASE1, PHASE2","title":"Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2017-10-23","conditions":"Acute Myeloid Leukemia","enrollment":62},{"nctId":"NCT00801489","phase":"PHASE2","title":"Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-04-04","conditions":"Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1","enrollment":270},{"nctId":"NCT07014462","phase":"PHASE1","title":"A Phase 1B Investigator Initiated Study of Safety and Tolerability of Dexamethasone (D) in Combination With Venetoclax-based Low-Intensity Therapy (LIT) in Treatment-Naïve Acute Myeloid Leukemia (AML): DLIT-AML","status":"ENROLLING_BY_INVITATION","sponsor":"University of Vermont","startDate":"2025-09-01","conditions":"AML - Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT04229979","phase":"PHASE3","title":"Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sellas Life Sciences Group","startDate":"2021-02-08","conditions":"Acute Myeloid Leukemia","enrollment":127},{"nctId":"NCT06429098","phase":"PHASE2","title":"Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-01-01","conditions":"Acute Myeloid Leukemia","enrollment":40},{"nctId":"NCT06474663","phase":"PHASE1","title":"A Phase I Study Investigating the Combination of Cladribine, Low Dose Cytarabine and Sorafenib Alternating With Decitabine in Pediatric Relapsed and Refractory Acute Leukemias","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2025-07-31","conditions":"Refractory Acute Leukemia, Relapsed Acute Leukemia","enrollment":""},{"nctId":"NCT04891757","phase":"PHASE1","title":"FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Foghorn Therapeutics Inc.","startDate":"2021-06-14","conditions":"Advanced Hematologic Malignancy, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":144},{"nctId":"NCT02937662","phase":"PHASE2","title":"Efficacy of Idarubicin, Cytarabine and Cyclophosphamide (IAC) Regimen in Relapsed/Refractory AML","status":"COMPLETED","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2016-10","conditions":"Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT05766514","phase":"PHASE2","title":"Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction","status":"WITHDRAWN","sponsor":"University of Florida","startDate":"2025-04","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":""},{"nctId":"NCT05586074","phase":"PHASE3","title":"HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML","status":"RECRUITING","sponsor":"Sunshine Lake Pharma Co., Ltd.","startDate":"2023-03-03","conditions":"Leukemia, Acute Myeloid (AML)","enrollment":324},{"nctId":"NCT06651866","phase":"PHASE1","title":"Dose-escalation Study of D-CMG Regimen for the Treatment of Elderly Newly Diagnosed AML Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2024-12-12","conditions":"Acute Myeloid Leukemia","enrollment":18},{"nctId":"NCT03092674","phase":"PHASE2, PHASE3","title":"Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-02-02","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myelodysplastic Syndrome/Acute Myeloid Leukemia","enrollment":76},{"nctId":"NCT04623944","phase":"PHASE1","title":"NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nkarta, Inc.","startDate":"2020-09-21","conditions":"Relapsed/Refractory AML, AML, Adult, MDS","enrollment":61},{"nctId":"NCT06741722","phase":"PHASE2","title":"Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML","status":"RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2024-10-31","conditions":"AML, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT02488408","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Multicenter Open-label Study of Bemcentinib (BGB324) in Patients With AML or MDS","status":"COMPLETED","sponsor":"BerGenBio ASA","startDate":"2014-10-22","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndromes","enrollment":122},{"nctId":"NCT02085408","phase":"PHASE3","title":"Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2011-02-04","conditions":"Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0)","enrollment":727},{"nctId":"NCT05177731","phase":"PHASE3","title":"Venetoclax + Decitabine vs. \"7+3\" Induction Chemotherapy in Young AML","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chen Suning","startDate":"2022-03-01","conditions":"AML, Adult, Chemotherapy Effect","enrollment":188},{"nctId":"NCT02920008","phase":"PHASE3","title":"Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2017-03-16","conditions":"Acute Myeloid Leukemia","enrollment":302},{"nctId":"NCT06316960","phase":"PHASE2","title":"Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation","status":"RECRUITING","sponsor":"Children's Hospital of Soochow University","startDate":"2024-03-01","conditions":"AML, Childhood, Relapse/Recurrence, Refractory AML","enrollment":50},{"nctId":"NCT05740449","phase":"PHASE1, PHASE2","title":"HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies","status":"WITHDRAWN","sponsor":"Princess Maxima Center for Pediatric Oncology","startDate":"2023-10-01","conditions":"Acute Lymphoblastic Leukemia, in Relapse, Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Recurrent, Lymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) Recurrent","enrollment":""},{"nctId":"NCT04113616","phase":"PHASE1, PHASE2","title":"An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)","status":"TERMINATED","sponsor":"Kartos Therapeutics, Inc.","startDate":"2019-09-25","conditions":"Relapsed or Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)","enrollment":70},{"nctId":"NCT02441803","phase":"PHASE2","title":"Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-09-14","conditions":"Leukemia","enrollment":11},{"nctId":"NCT05456269","phase":"PHASE1","title":"A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS","status":"WITHDRAWN","sponsor":"Race Oncology Ltd","startDate":"2022-07-29","conditions":"Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":""},{"nctId":"NCT03882203","phase":"PHASE2","title":"CLAGE Sequential With Flu-Bu Conditioning for Refractory Acute Leukemia","status":"COMPLETED","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2018-08-01","conditions":"Refractory Hematologic Cancer, Allogeneic Stem Cell Transplantation","enrollment":18},{"nctId":"NCT02665065","phase":"PHASE3","title":"Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Actinium Pharmaceuticals","startDate":"2016-06","conditions":"Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute","enrollment":153},{"nctId":"NCT03236857","phase":"PHASE1","title":"A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-11-08","conditions":"Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML)","enrollment":143},{"nctId":"NCT05805072","phase":"NA","title":"Selinexor and HAAG With/Without HMA in Relapsed/Refractory Acute Leukemia (AML) Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2023-05-01","conditions":"Relapsed/Refractory AML","enrollment":20},{"nctId":"NCT03303339","phase":"PHASE1, PHASE2","title":"Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"Cardiff Oncology","startDate":"2017-11-17","conditions":"Acute Myeloid Leukemia","enrollment":72},{"nctId":"NCT02172872","phase":"PHASE3","title":"\"InDACtion\" vs \"3+7\" Induction in AML","status":"UNKNOWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2014-11-28","conditions":"Acute Myeloid Leukemia (AML)","enrollment":606},{"nctId":"NCT02551718","phase":"NA","title":"High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-09-11","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia","enrollment":34},{"nctId":"NCT01177540","phase":"PHASE2","title":"Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects","status":"TERMINATED","sponsor":"Eisai Inc.","startDate":"2011-03-03","conditions":"Pediatric Acute Myelogenous Leukemia (AML)","enrollment":25},{"nctId":"NCT05382390","phase":"PHASE3","title":"Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen in Acute Myeloid Leukemia: Study Protocol for a Randomized Controlled Trial","status":"UNKNOWN","sponsor":"Huihan Wang","startDate":"2022-01-21","conditions":"Acute Myeloid Leukemia","enrollment":130},{"nctId":"NCT05362942","phase":"PHASE2","title":"Combination of Venetoclax, Hypomethylation Agent and Low-dose Cytarabine as a Salvage Therapy for Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Beijing 302 Hospital","startDate":"2022-05-01","conditions":"Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Minimal Residual Disease","enrollment":52},{"nctId":"NCT03217838","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants.","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2017-07-31","conditions":"Acute Myeloid Leukaemia","enrollment":50},{"nctId":"NCT03985007","phase":"PHASE2","title":"CDIAG Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2018-01-01","conditions":"Acute Myeloid Leukemia, Relapsed, Adult","enrollment":40},{"nctId":"NCT05258799","phase":"NA","title":"Dual Growth Factor (rhTPO + G-CSF) and Chemotherapy Combination Regimen for Elderly Patients With Acute Myeloid Leukemia: A Phase II Single-Arm Multicenter Study","status":"UNKNOWN","sponsor":"Huihan Wang","startDate":"2022-01-21","conditions":"Acute Myeloid Leukemia","enrollment":130},{"nctId":"NCT00740181","phase":"PHASE2","title":"Decitabine, Cytarabine, GCSF for Refractory AML/MDS","status":"TERMINATED","sponsor":"Brown University","startDate":"2008-08","conditions":"Myelodysplasia, Leukemia","enrollment":9},{"nctId":"NCT05123352","phase":"","title":"Investigation of the Gut Microbiota in Acute Myeloid Leukemia Receiving Two Different Induction Therapies","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-11","conditions":"Acute Myeloid Leukemia, Adult, Gut Microbiota","enrollment":60},{"nctId":"NCT03257241","phase":"PHASE3","title":"A PALG Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in AML Patients ≤ 60 Years Old","status":"UNKNOWN","sponsor":"Polish Adult Leukemia Group","startDate":"2017-07-03","conditions":"Acute Myeloid Leukemia","enrollment":582},{"nctId":"NCT04945096","phase":"PHASE3","title":"Outcomes of Patients After Allo-HSCT With Decitabine and NAC","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2021-07-01","conditions":"Engraft Failure, Relapse, GVHD","enrollment":100},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT04582604","phase":"PHASE1, PHASE2","title":"Ruxolitinib and Decitabine for High Risk Hematological Malignancies","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2020-09-01","conditions":"Peripheral Blood Stem Cell Transplantation","enrollment":60},{"nctId":"NCT04373395","phase":"NA","title":"Decitabine+Cladribine+Cytarabine+Granulocyte Colony-stimulating Factor (D-CLAG) for Relapsed or Refractory Acute Myeloid Leukemia (AML)","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2020-01-01","conditions":"Acute Myeloid Leukemia","enrollment":65},{"nctId":"NCT04541277","phase":"PHASE2","title":"Combined Inhibition of PD-1 and DNA Hypomethylating Agent +/- Chemotherapy in High-risk AML or Elderly Patients With AML Who Are Unfit for Intensive Chemotherapy","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2020-09-01","conditions":"Acute Myeloid Leukemia, in Relapsed or Refractory, Acute Myeloid Leukemia, Elderly, Unfit, Acute Myeloid Leukemia With Positive Minimal Residual Disease","enrollment":55},{"nctId":"NCT04446130","phase":"PHASE3","title":"Study of Decitabine Combined With HAAG Regimen in Newly Diagnosed ETP-ALL/LBL, T/M-MPAL and ALL/LBL With Myeloid or Stem Cell Markers Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2019-01-01","conditions":"Induction Chemotherapy, Acute T-Lymphocytic Leukemia, T-cell Lymphoblastic Lymphoma Leukemia","enrollment":100},{"nctId":"NCT03417427","phase":"PHASE2","title":"A Clinical Trail of Demethylation Drug Combined With Chemotherapy in Intermediate-risk AML","status":"UNKNOWN","sponsor":"Xuejie Jiang","startDate":"2018-02-01","conditions":"Leukemia, Myeloid","enrollment":100},{"nctId":"NCT02921061","phase":"PHASE1, PHASE2","title":"Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2016-11-17","conditions":"Mixed Phenotype Acute Leukemia, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia","enrollment":28},{"nctId":"NCT03793517","phase":"PHASE2, PHASE3","title":"Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2018-09-01","conditions":"Stem Cell Transplant Complications, Leukemia, Myeloid, Acute, Leukemia Relapse","enrollment":55},{"nctId":"NCT01546038","phase":"PHASE2","title":"A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-06-27","conditions":"Acute Myeloid Leukemia","enrollment":255},{"nctId":"NCT02272478","phase":"PHASE2, PHASE3","title":"Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations","status":"UNKNOWN","sponsor":"Cardiff University","startDate":"2014-10-30","conditions":"Acute Myeloid Leukaemia, Myelodysplastic Syndrome","enrollment":1600},{"nctId":"NCT02954653","phase":"PHASE1","title":"A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Pfizer","startDate":"2016-11-28","conditions":"Acute Myeloid Leukemia","enrollment":8},{"nctId":"NCT04168138","phase":"NA","title":"D-CTAG in the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients","status":"UNKNOWN","sponsor":"Huihan Wang","startDate":"2019-11-01","conditions":"Acute Myeloid Leukemia","enrollment":20},{"nctId":"NCT02343939","phase":"PHASE1, PHASE2","title":"Entospletinib Monotherapy and in Combination With Chemotherapy in Adults With Acute Myeloid Leukemia (AML)","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2015-07-01","conditions":"Acute Myeloid Leukemia","enrollment":148},{"nctId":"NCT01829503","phase":"PHASE2","title":"Phase II Study of Decitabine and Cytarabine for Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"Annie Im, M.D.","startDate":"2013-02","conditions":"Acute Myeloid Leukemia","enrollment":44},{"nctId":"NCT04087967","phase":"PHASE3","title":"Study of DAC Combined With HAAG Regimen in Newly Diagnosed Younger AML Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2019-04-01","conditions":"Acute Myeloid Leukemia, Induction Chemotherapy","enrollment":162},{"nctId":"NCT00260832","phase":"PHASE3","title":"Trial of Decitabine in Patients With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2005-11","conditions":"Acute Myeloid Leukemia","enrollment":485},{"nctId":"NCT04083911","phase":"PHASE3","title":"Study of DAC Combined With HAAG Regimen in Newly Diagnosed AML Patients Older Than 60","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2019-04-01","conditions":"Acute Myeloid Leukemia, Induction Chemotherapy","enrollment":50},{"nctId":"NCT01853228","phase":"PHASE1, PHASE2","title":"A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-10-22","conditions":"Acute Myeloid Leukemia","enrollment":17},{"nctId":"NCT02662647","phase":"PHASE2","title":"Decitabine Based Chemotherapy Followed by Haploidentical Lymphocyte Infusion for Elderly Patients With AML","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2015-04","conditions":"AML","enrollment":30},{"nctId":"NCT01794702","phase":"PHASE1, PHASE2","title":"Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2013-02-20","conditions":"Leukemia","enrollment":65},{"nctId":"NCT03799224","phase":"PHASE2, PHASE3","title":"Decitabine Plus mBU/CY Preconditioning for Relapse/Refractory Acute Leukemia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2018-12-01","conditions":"Stem Cell Transplant Complications, Relapse Leukemia, Refractory Leukemia","enrollment":55},{"nctId":"NCT00416598","phase":"PHASE2","title":"Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2006-11-15","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11","enrollment":546},{"nctId":"NCT01729845","phase":"PHASE1, PHASE2","title":"Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2012-12-20","conditions":"Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia","enrollment":52},{"nctId":"NCT02323607","phase":"PHASE1","title":"Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations","status":"COMPLETED","sponsor":"Bhavana Bhatnagar","startDate":"2016-01-12","conditions":"Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia","enrollment":13},{"nctId":"NCT02412475","phase":"PHASE1","title":"Epigenetic Reprogramming in Relapse AML","status":"TERMINATED","sponsor":"Michael Burke","startDate":"2015-02-21","conditions":"Leukemia, Acute Myeloid","enrollment":3},{"nctId":"NCT03579082","phase":"PHASE4","title":"A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma","status":"UNKNOWN","sponsor":"Mingzhi Zhang","startDate":"2018-06-01","conditions":"Diffuse Large B Cell Lymphoma","enrollment":60},{"nctId":"NCT03662087","phase":"PHASE2, PHASE3","title":"HMA+DLI vs DLI Preemptive Therapy Based on MRD for AL Undergoing Allo-HSCT","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2018-10","conditions":"Minimal Residual Disease,Acute Leukemia, Hypomethylating Agents, Donor Lymphocyte Infusion, Allogeneic Hematopoietic Cell Transplantation","enrollment":100},{"nctId":"NCT02532010","phase":"PHASE2","title":"Pacritinib Combined With Decitabine or Cytarabine in Older Patients With AML","status":"TERMINATED","sponsor":"Weill Medical College of Cornell University","startDate":"2015-06-15","conditions":"Acute Myeloid Leukemia (AML)","enrollment":13},{"nctId":"NCT02121418","phase":"NA","title":"Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm","status":"COMPLETED","sponsor":"University of Washington","startDate":"2014-06","conditions":"Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome, Myeloproliferative Neoplasm","enrollment":12},{"nctId":"NCT03453255","phase":"PHASE1, PHASE2","title":"DCHA as Postremission Therapy for AML With t(8;21)","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2018-01-01","conditions":"Chemotherapy","enrollment":120},{"nctId":"NCT02886559","phase":"PHASE1, PHASE2","title":"Chidamide Plus DCAG for Relapsed/Refractory AML","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2016-06","conditions":"AML, Relapse","enrollment":100},{"nctId":"NCT03381781","phase":"PHASE2","title":"Decitabine,Cytarabine and Arsenic Trioxide for Acute Myeloid Leukemia With p53 Mutations","status":"UNKNOWN","sponsor":"Li Junmin","startDate":"2018-03","conditions":"Acute Myeloid Leukemia, P53 Mutation","enrollment":100},{"nctId":"NCT00882206","phase":"PHASE2","title":"Pre-reinductive Decitabine and Vorinostat in Relapsed Lymphoblastic Lymphoma or Acute Lymphoblastic Leukemia","status":"TERMINATED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2009-04","conditions":"Leukemia, Lymphoma","enrollment":15},{"nctId":"NCT02850822","phase":"","title":"Effect of Chemotherapy vs No Chemotherapy Pre-transplant to MDS Undergoing Allo-HSCT","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2016-07","conditions":"Myelodysplastic Syndrome, Chemotherapy","enrollment":250},{"nctId":"NCT03356080","phase":"PHASE2","title":"DLAAG in the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome With Blast Excess","status":"UNKNOWN","sponsor":"Shanghai Tong Ren Hospital","startDate":"2017-07-07","conditions":"Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":50},{"nctId":"NCT03256071","phase":"PHASE2, PHASE3","title":"Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2017-09","conditions":"Acute Myeloid Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning","enrollment":90},{"nctId":"NCT01130506","phase":"PHASE1","title":"Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2010-05-17","conditions":"Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":17},{"nctId":"NCT01607645","phase":"PHASE2","title":"Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2012-07","conditions":"Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b)","enrollment":7},{"nctId":"NCT01567059","phase":"PHASE2","title":"Tosedostat in Combination With Cytarabine or Decitabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2012-05","conditions":"Acute Myeloid Leukemia With Multilineage Dysplasia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q)","enrollment":34},{"nctId":"NCT03026842","phase":"PHASE4","title":"Decitabine Versus Conventional Chemotherapy for Maintenance Therapy of Acute Myeloid Leukemia With t(8;21)","status":"UNKNOWN","sponsor":"The First Hospital of Jilin University","startDate":"2017-01","conditions":"Acute Myeloid Leukemia","enrollment":180},{"nctId":"NCT02985372","phase":"PHASE3","title":"Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia","status":"UNKNOWN","sponsor":"Chunyan Ji","startDate":"2016-12","conditions":"Acute Myeloid Leukemia, Adult","enrollment":30},{"nctId":"NCT02084563","phase":"PHASE2","title":"Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2012-10","conditions":"Acute Myeloid Leukemia, Myeloproliferative Neoplasms, Myelodysplastic Syndromes","enrollment":455},{"nctId":"NCT01417767","phase":"PHASE2, PHASE3","title":"Efficacy Study of CHG Regimen vs Decitabine to Treat Higher-risk MDS","status":"UNKNOWN","sponsor":"Xiao Li","startDate":"2011-09","conditions":"Myelodysplastic Syndromes","enrollment":50},{"nctId":"NCT02845232","phase":"","title":"Economic Analysis of Blood Product Transfusions According to the Treatment of Acute Myeloid Leukaemia in the Elderly","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2013-03","conditions":"Acute Myeloid Leukemia","enrollment":214}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"decitabine and cytarabine","genericName":"decitabine and cytarabine","companyName":"Annie Im, M.D.","companyId":"annie-im-m-d","firstApprovalDate":"","aiSummary":"Decitabine is used to treat Acute Myeloid Leukemia, particularly in older patients. It is often compared to low-dose cytarabine or supportive care in clinical trials, and can be used in combination with cytarabine.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}